Introduction

Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. It is the most frequent cancer both in terms of incidence (1.2 million new cases, 12.3% of the global total) as well as with respect to mortality, approximately 1.2 million deaths per year, which is equivalent to 17.8% of the world total (1).

Patients with NSCLC experience poor overall survival (OS) (2) due to the presence of metastatic diseases that are not adequately detected and therefore many patients are subjected to aggressive localized treatments, such as surgery or radiotherapy (RT), when in reality they present advanced distant disease.

Tissue biopsy has always been the standard diagnostic procedure for tumors and also to provide enough material for genotyping, which can assist in the targeted therapies of cancers. However, tissue biopsy-based cancer diagnostic procedures have limitations in their assessment of cancer development, prognosis and genotyping, due to tumor heterogeneity and evolution (3). As a matter of fact, there is growing evidence for intratumor heterogeneity indicating that single-site biopsies fall short of revealing the complete genomic landscape of a tumor (4).

A liquid biopsy, or blood sample, can provide the genetic landscape of all cancerous lesions (primary and metastases). In addition, it offers the opportunity to systematically monitor cancer disease as the quantification of circulating...
tumor DNA (ctDNA) has been shown to correlate with tumor burden (5). Circulating free DNA (cfDNA), exosomal RNA as well as circulating tumor cells (CTCs) or tumor-educated platelets (TEP) offer the potential for non-invasive screening, diagnosis, prognosis, and measuring response to treatment (6-8).

The practice of liquid biopsy as a diagnostic and prognostic tool in lung cancer patients is gradually becoming an appealing approach in the clinical routine practice, since it is noninvasive and can be easily repeated (3). In particular, this approach allows real-time monitoring of the patient during treatment, as well as the detection of different genomic alterations potentially sensitive to targeted therapy or associated with treatment resistance. It also allows rapid access to biomarker assessment in vulnerable lung cancer patients for whom solid biopsies are inaccessible or difficult to repeat. This attractive approach could promote a change in therapy, even before detection of tumor progression or relapse (5).

This Review will explore how tumor-associated genetic alterations detectable in the blood can be used in the clinic for diagnosis, assessment of prognosis, early detection of disease recurrence, and as surrogates for traditional biopsies with the purpose of predicting response to treatments and the emergence of acquired resistance.

**Liquid biopsy**

The term “liquid biopsy” qualifies different potential approaches for the detection of biomarkers found in circulating blood in cancer patients. Liquid biopsy analysis is a rapidly expanding field in translational cancer research and might be useful at different points of the diagnostic/therapeutic course of cancer patients, such as early diagnosis, estimation of the risk for metastatic relapse or metastatic progression (prognostic information), stratification and real-time monitoring of therapies, identification of therapeutic targets and resistance mechanisms (predictive information), and understanding metastasis development in cancer patients. Different liquid-derived materials can be employed, such as CTCS, ctDNA, exosomes, circulating RNA or microRNAs (9). They may be obtained from almost all body fluids (blood, serum, plasma, urine, pleural effusion, ascites, etc.) (10) and are likely to contain a wider presentation of genomic data from multiple metastatic sites, whereas mutations present in a single biopsy or minor subclone may be missed. In addition, the information obtained from liquid biopsies is allowing an increase into the knowledge of the pathophysiology of lung cancer and into the process of metastatic dissemination.

Molecular profiling studies performed on tumor biopsies of NSCLC have identified genetic alterations that predict tumor responses to targeted therapies such as protein tyrosine kinase inhibitors (TKI). With an even larger repertoire of TKI entering the clinic, screening tumors for genomic aberrations is increasingly important (11). Detection of these driver mutations, such as EGFR mutations, in cfDNA or CTCs, has allowed to use targeted therapies avoiding invasive procedures and to identify resistance mechanisms for TKIs, while quantification of these mutations has helped to monitor tumor burden and dynamics (12,13). However, the mutational analysis of cfDNA demonstrated a significantly better sensitivity when compared with CTCs, establishing cfDNA as the best source of material for mutation detection (14).

In addition, the biological properties of mRNA content of exosomes and platelets have also contributed to provide a comprehensive real-time picture of the tumor burden, improving the application of genetic profiling of tumor associated RNA and DNA derived from biofluids and the understanding of cancer as a dynamic disease.

**CTCs**

CTCs are formed by cell detachment from the primary tumor mass, determining the migration of tumor cells to secondary sites via the lymphatic and blood system. The presence of CTCs has been demonstrated in the blood of patients with various solid tumors and it has been associated with poor outcome in metastatic NSCLC patients as well as in other tumors (10,15). Although CTCs were first described in 1869, their possible role in the clinical setting since has progressively gained attention (16).

Detection of CTCs is technically challenging since it is estimated that as few as one CTCs can be found per $10^{5}$–$10^{6}$ peripheral blood mononuclear cells in patients with advanced solid tumors, with less quantity of cells in patients with early-stage diseases. Due to this low concentration of CTCs, its detection and characterization require highly sensitive and specific methods, which consist in a combination of different strategies (17).

CTCs enrichment is either based on biological or physical properties (18). Biological properties include those approaches targeting epithelial specific surface markers like epithelial cell adhesion molecule (EpCAM) for positive selection (e.g., CellSearch™, microfluidic devices or the
CTCs detection as a diagnosis marker of NSCLC. CTCs were labeled by a folate receptor (FR) conjugate, showing a sensitivity of 73.2% and a specificity of 84.1% for the diagnosis of NSCLC (67.2% sensitivity in stage I). Of note, FRs are highly expressed in a variety of tumors, particularly in ovarian and lung cancers, whereas most normal tissues express low to negligible levels. A novel FR-based CTCs analysis method had been developed based on these findings (27).

CTCs have long been considered to reflect tumor aggressiveness and have been investigated as a surrogate marker for tumor growth. At this respect, the decrease in the number of CTCs during the treatment has been associated with radiographic tumor response and an increase in the cell counts with tumor progression (9). In particular, the decrease or disappearance of CTCs following surgery has been correlated with improved clinical outcomes (28,29). A recent study (30) has prospectively analysed the kinetics of CTCs in blood samples of 56 patients obtained before surgery and one month after. The results showed that the presence of CTCs after surgery was significantly associated with early recurrence (P=0.018) and a shorter disease-free survival (DFS) (P=0.008).

Changes in CTCs count after RT have also been studied. Dorsey et al. (31) analyzed 30 patients with localized NSCLC undergoing radiation treatment. Using a telomerase-based detection assay, 65% of them were CTCs positive prior to treatment, but CTCs numbers significantly dropped after irradiation (9.1 vs. 0.6 CTCs/mL; P<0.001).

In metastatic NSCLC patients, a number of studies have reviewed the prognostic significance of baseline CTCs count, concluding that it is an independent negative prognostic factor that correlates with advanced stage a shorter progression-free survival (PFS) and OS (21). Using the CellSearch system, Krebs et al. (21) reported median OS of 8.1 vs. 4.3 months (P<0.001) and PFS of 6.8 vs. 2.4 months (P<0.001) for stage III–IV NSCLC patients when CTCs cut-offs of ≥2 were applied. In the multivariate analysis, the number of CTCs was the strongest predictor of OS (HR 7.92; 95% CI, 2.85–22; P<0.001) exceeding the traditional risk factors of stage and performance status. In another study including 46 patients with newly diagnosed or recurrent NSCLC, CTCs were measured at baseline and before every chemotherapy cycle in a subset of patients (n=23). A baseline CTCs count of more than eight prior to chemotherapy was a strong predictor of reduced PFS (P=0.018) and OS (P=0.026). However, no correlation was observed between CTCs count and tumor size after two chemotherapy cycles (32).
Finally, several studies have provided evidence of an association between a decrease in CTCs counts and radiographic response by FDG-PET/CT or RECIST. In a phase II clinical trial of erlotinib and pertuzumab with 41 patients enrolled, higher baseline CTCs counts were associated with better response to treatment by RECIST (P=0.009), and decreased CTCs counts after treatment correlated with FDG-PET and RECIST responses (P=0.014 and P=0.019) and a longer PFS (P=0.05) (14). However, a more recent study failed to confirm this finding, probably because it included a heterogeneous cohort of patients with respect to stage and histology, which can confound interpretation of FDG uptake and CTCs analysis (33).

In all, these studies indicate that CTCs count might be useful as a prognostic marker in lung cancer patients and can be of helpful in therapy decision making, especially for the selection of those surgically rejected patients at a higher risk of relapse who might benefit from adjuvant therapies (5).

Biomarker detection in CTCs

The development of personalized medicine and targeted therapies has led to an increased interest in CTCs as a source of material for genetic analyses. The detection and characterization of CTCs represent a major opportunity as they reflect both the phenotypic and the genetic information of the primary tumors. Also, the analysis of CTCs allows real-time evaluation of metastasis and can show the molecular condition of the disease (10).

EGFR status has been examined in CTCs from advanced NSCLC patients, allowing the identification of sensitizing mutations and the T790M resistant mutation. Using the CellSearch System coupled with next-generation sequencing (NGS), Marchetti et al. (34) identified for the first time EGFR mutations in the CTCs of 84% of patients EGFR positive in matching tumor tissue. In another study (35), a novel assay based on real-time PCR and melting curve analysis was developed to detect activating EGFR mutations in blood cell fractions enriched in CTCs. Using this assay, EGFR-positive CTCs were detected in pretreatment blood samples from all eight EGFR-mutant lung cancer patients studied (35).

Despite good initial responses, all NSCLC patients carrying sensitive EGFR mutations eventually develop resistance to EGFR-TKIs. The T790M gatekeeper mutation is present in 40–60% of those patients at disease progression. The development of third-generation EGFR inhibitors capable of overcoming T790M-associated resistance has led to a need for noninvasive testing of the T790M mutation (36). In a recent study comparing tumor biopsies with simultaneously collected CTCs and ctDNA, the resistance-associated mutation was detected in 47% to 50% of patients respectively, with a concordance ranging from 57% to 74%. (37). In those patients where the paired biopsy was negative or inconclusive, CTCs and ctDNA-based assays together enabled genotyping in 35% of cases.

ALK rearrangements, which are tested in NSCLC for crizotinib treatment, have also been evaluated in CTCs using a filtration enrichment technique and filter-adapted fluorescent in situ hybridization (FA-FISH). All ALK-positive patients were found to have four or more ALK-rearranged CTCs per mL of blood (median, 9 CTCs/mL; range, 4–34 CTCs/mL). In contrast, 0 to 1 ALK-rearranged CTCs/mL were detected in ALK-negative patients (median, 1; range, 0–1). The assay not only enabled diagnostic testing but also monitoring of crizotinib treatment (38). Similarly, ROS1 rearrangements, another target for crizotinib-based therapy, have been detected using ISET and FA-FISH in the CTCs of 4 patients with positive paired tumors for ROS1-gene (39).

In spite of all these technological advances, CTCs are still not used in the routine clinical practice or as a source of material for biomarker analysis in advanced NSCLC. Although FDA approved CellSearch as CTCs detection method in metastatic breast, prostate and colon cancer, it has not yet been approved in metastatic lung cancer patients. Several limitations such as the lack of epithelial biomarkers which hamper CTCs detection, the lack of validation in large multicenter studies to evaluate reproducibility, specificity and sensibility and the lack of clinical validation in different cohorts of lung cancer patients highlight the need of additional research in advanced NSCLC in order to implement its application in the clinical setting (5).

Circulating free tumor DNA

cT DNA has the potential to enable noninvasive diagnostic testing for personalized medicine since it can provide similar molecular information as invasive tumor biopsies. Currently, the evaluation of specific predictive biomarkers is mandatory for a proper treatment of advanced-stage NSCLC patients according to the molecular characterization of the disease. In some cases, this molecular profiling can be difficult due to a reduced availability of tumor tissue, and therefore ctDNA testing might be used as a surrogate.
cfDNA is single- or double-stranded DNA (dsDNA) that exists in plasma or serum. Early studies showed that many cancer-associated molecular characteristics, such as single-nucleotide mutations, methylation changes and cancer-derived viral sequences can be found in the cfDNA. These findings were significant for the development of ctDNA detection technology. Nevertheless, ctDNA-based assays face several challenges. Body cells release cfDNA into the bloodstream, but the majority of cfDNA is often not of cancerous origin, making it sometimes difficult to detect tumor-derived alterations (9). Also, prior knowledge about particular mutations can be of help, but may be difficult to obtain. However, recent technological advances have overcome these limitations, making it possible to identify both genetic and epigenetic alterations in cfDNA of cancer patients (3).

The fraction of cfDNA that is tumor derived in cancer patients ranges from <0.1% to >30% of the total DNA, and depends on tumor burden, stage, cellular turnover, accessibility to circulation and factors affecting blood volume. The ctDNA released by tumor cells will carry the same genetic (somatic) alterations as the tumor itself and this genetic load can be detected and quantified. At this respect, the relative levels of ctDNA have been shown to correlate with tumor burden and response to therapy (40).

Technical developments have allowed the identification of low frequency alterations in cfDNA. These platforms include real-time quantitative PCR (qPCR); digital PCR (dPCR); beads, emulsion, amplification and magnets (BEAMing); and NGS. The sensitivity of these techniques ranges from 15% to 0.01%, and one of the major obstacles for their clinical applicability is the lack of standardization (41).

Real time qPCR: real time qPCR has been widely used for the identification of genetic alterations and the quantification of nucleic acids. While qPCR is a standardized, relatively inexpensive technique, its precision for quantifying rare allele or genetic alterations present at very low levels is significantly lower compared to other techniques such as digital (dPCR) (42). However, most of the published studies adopted variants of this technology for the analysis of ctDNA in lung cancer.

Regarding detection of EGFR mutations in cfDNA using qPCR, Kimura et al. showed for the first time that plasma-derived EGFR genotype is predictive of subsequent clinical response to an EGFR-TKI. A 72.7% concordance was found in the cases analyzed by sequencing of the primary tumor and Scorpion ARMS assay of plasma, (43). Similarly, Mok et al. reported a concordance between tissue and cfDNA of 88%, with blood test sensitivity of 75% and a specificity of 96% using the cobas blood test, based on qPCR (44).

EGFR oncogenic mutations have also been analyzed in plasma cfDNA of patients included into different trials, such as a trial evaluating the combination of pertuzumab and erlotinib (14) or the IPASS trial (45), which compared gefitinib with carboplatin/paclitaxel. The sensitivity of ctDNA testing in identifying EGFR mutations compared with tumor tissue ranged from 43% to 100%, being able to identify EGFR mutations in patients with insufficient or unevaluable tissue.

dPCR: the unparalleled precision of this technology enables accurate measurements for the quantification of low frequency genetic alterations. In this methodology, target molecules are separated into a large number of partitions so that each partition receives a number of molecules (usually ranging from 0–2) theoretically following a Poisson distribution. In consequence, target molecules are amplified mostly on an individual basis and measurements rely on counting the total of positive partitions containing one or more target molecules and negative partitions where no amplification is detected. dPCR allows for the detection of mutated ctDNA in a high background of wild type cfDNA and for the quantification of small fold change differences. Several studies have assessed the feasibility of dPCR for biomarker testing and cancer monitoring and have evidenced that dPCR is indeed an adequate technology for such purpose (44-48).

BEAMing: this technique is based on a combination of emulsion dPCR with magnetic beads and flow cytometry for detection and quantification of mutant tumor DNA molecules (49). BEAMing is a highly sensitive but complex method to detect genetic mutations at very low levels (50). This methodology has been compared to mutation analysis of tumor tissue in a recent publication that tested 21 mutations in BRAF, EGFR, KRAS and PIK3CA in samples from different cancer types (13.8% of NSCLC). Results were concordant for archival tissue and plasma cfDNA in 91% cases for BRAF mutations, in 99% cases for EGFR mutations, in 83% cases for KRAS mutations and in 91% cases for PIK3CA mutations, demonstrating that BEAMing is feasible and highly concordant with tumor tissue analysis (51). Parallely, Taniguchi et al. used this technology for plasma testing of EGFR mutations (52) in 44 patients with EGFR mutant NSCLC (23 with progressive disease after TKI and 21 TKI-naïve). Activating mutations were detected in the cfDNA of 72.7% of the patients, while the T790M was found in 43.5% of the cases with a progressive disease.
To assess the ability of different technologies to detect \textit{EGFR} mutations in ctDNA, including T790M, a comparison of multiple platforms was undertaken (53). It included two non-digital (cobas\textsuperscript{TM} \textit{EGFR} mutation Test and therascreen\textsuperscript{TM} \textit{EGFR} amplification refractory mutation system assay) and two digital platforms (DropLet Digital\textsuperscript{TM} PCR and BEAMing digital PCR). This study used samples from a trial that investigated the safety and efficacy of AZD9291, a third-generation \textit{EGFR}-TKI, in patients with a sensitizing mutation whose disease progressed after a TKI. For \textit{EGFR}-TKI-sensitizing mutations, high sensitivity (78–100\%) and specificity (93–100\%) versus tissue was observed using the four platforms. Regarding the T790M mutation, the digital platforms outperformed the non-digital platforms. Subsequent assessment using 72 additional baseline plasma samples was conducted using the cobas \textit{EGFR} mutation Test and BEAMing dPCR and using a tissue test result as a non-reference standard. For the T790M detection, the sensitivity and specificity were 73\% and 67\% for the first technology and 81\% and 58\%, respectively, with a concordance between the platforms >90\%. Another recent publication comparing BEAMing and cobas test showed a higher concordance between BEAMing plasma and tumor \textit{EGFR} results than between cobas \textit{EGFR} plasma and tumor (82\% for activating mutations and 73\% for T790M using BEAMing vs. 73\% and 64\%, respectively, using cobas plasma test) (54).

NGS: the emerging of new drugs that target other genomic alterations than \textit{EGFR} mutations have significantly increased the complexity of biomarker testing. In the context of a growing number of driver mutations to test, NGS presents itself as a suitable technology since it allows simultaneous detection of multiple alterations in a very efficient manner. However, the use of this technology might be limited by a modest sensitivity. Using deep sequencing as a detection system for \textit{EGFR} mutation in the ctDNA of stage I–IV NSCLC patients, Uchida \textit{et al.} reported a diagnostic sensitivity and specificity for exon 19 deletions of 50.9\% and 98\%, respectively; and for the L858R mutation of 51.9\% and 94.1\%. Although overall sensitivity was 54.4\% for all cases; it dropped to 22.2\% in stages IA-IIIA, compared to 72.7\% in stages IIIB–IV, highlighting that NGS might be restricted to advanced disease (55). Similarly, Couraud \textit{et al.} used the Ion Torrent Personal Genome Machine for the deep sequencing of the most relevant hotspot somatic mutations (\textit{EGFR}, \textit{BRAF}, \textit{KRAS}, \textit{HER2}, and \textit{PIK3CA}) in tumor and plasma cfDNA of never-smoker NSCLC patients. In ctDNA, 50 mutations (36 \textit{EGFR}, 5 \textit{HER2}, 4 \textit{KRAS}, 3 \textit{BRAF}, and 2 \textit{PIK3CA}) were identified. Sensitivity of the test was 58\% and the estimated specificity was 87\% (56). Because sensitivity appears to be compromised in early stages, several strategies to solve this issue are being tested. Newman \textit{et al.} have developed an ultrasensitive method for quantifying ctDNA that can detect ctDNA in 100\% of patients with stage II–IV NSCLC and 50\% of patients with stage I, with 96\% specificity for mutant allele fractions down to 0.02\%. Researchers communicated that ctDNA levels correlated with tumor volume and distinguished between residual disease and treatment-related imaging changes. Measurement of ctDNA levels allowed for earlier response assessment compared to radiographic approaches, facilitating personalized cancer therapy (57). However, low quantities of ctDNA in blood and sequencing artifacts could limit the analytical sensitivity of this methodology. To overcome these limitations, the same groups have recently developed other technological approaches for improved detection of ctDNA (58).

Finally, two meta-analyses exploring the diagnostic value of cfDNA for the detection of \textit{EGFR} mutation status have been published (59,60). Luo \textit{et al.} [2014] reviewed 20 studies involving 2012 cases to assess the diagnostic performance of cfDNA compared with tumor tissue and concluded that detection of \textit{EGFR} mutations in cfDNA has an adequate diagnostic accuracy. Likewise, Qiu \textit{et al.} [2015] analysed 27 studies involving 3,110 patients and reported effectiveness similar to Luo \textit{et al.}, with overall sensitivity of 62\%, specificity of 96\% and diagnostic odds ratio of 38.270.

**Exosomes**

Exosomes are vesicles of endocytic origin with a diameter of 40–100 nm that transfer information to the target cells (including proteins, DNA, mRNA, as well as non-coding RNAs) through at least three mechanisms: fusion with the plasma membrane, receptor-ligand interaction or endocytosis by phagocytosis (61). Thakur \textit{et al.} provided also evidence that tumor-derived exosomes carry dsDNA, showing that exosomal DNA could reflect the mutational status of parental tumor cells (62).

Exosomes are critically involved in tumor initiation, growth, progression, metastasis, and drug resistance by transferring oncogenic proteins and nucleic acids. The role of exosomes in modulating the pathways that lead to the development of resistance to both RT and chemotherapy is an emerging area of intense research. Therefore, exosomes and their load could be biomarkers with value in diagnosis,
Blood platelets have recently emerged as important players in cancer development and responses to tumor growth. The confrontation of these platelets with tumor cells via transfer of tumor-associated biomolecules has been named “education”. This interaction induces, among other processes, specific splicing of pre-mRNAs (69). In addition, platelets can ingest circulating RNA (70). Taken together, it appears that TEP could be a suitable source of material for liquid biopsy-based analyses. A recent publication by Best et al. (71) developed a classifier based on RNA-Seq of TEPs. Across six primary tumor types (NSCLC, colorectal carcinoma, glioblastoma, pancreatic cancer, hepatobiliary cancer, and breast cancer), the location of the primary tumor was correctly identified with 71% accuracy. Moreover, they identified several genetic alterations or biomarkers that could guide the use of drugs targeting those mutations. In addition to exosomes, TEPs seem to be an adequate source for fusion gene identification in liquid biopsies. Nilsson et al. have examined the use of RT-PCR to detect EML4-ALK rearrangements in platelets and plasma compared with matched tissue biopsies. RT-PCR demonstrated 65% sensitivity and 100% specificity for the detection of EML4-ALK rearrangements in platelets. Intriguingly, in a subset of 29 patients treated with crizotinib, the detection of these rearrangements in platelets was found to be correlated with lower PFS and OS. Authors also concluded that monitoring of EML4-ALK rearrangements in the platelets of one patient over a period of 30 months revealed crizotinib resistance two months prior to radiographic disease progression (72).

Collectively, these data suggest that TEP may provide a RNA BioSource for liquid biopsy based diagnosis (73).

**Conclusions**

Personalized medicine in oncology relies on the customization of healthcare using molecular analyses. In this context, diagnostic testing is used to select appropriate and optimal therapies based on a patient’s cancer genome and to obtain molecular biomarkers in an easily accessible, minimally invasive way in order to follow the molecular profile of a patient’s tumor longitudinally. The clinical application of liquid biopsy in NSCLC is progressively proving a pivotal tool for screening and early detection of cancer, real-time monitoring of therapy or risk of relapse (prognosis) and identification of therapeutic targets and resistance mechanisms.

tcDNA and CTCs in NSCLC patients are being intensively investigated, as they have proven to provide a
dynamic picture of molecular disease changes and can be used to identify molecular alterations emerging during the course of treatment in a noninvasive manner. It is becoming increasingly clear that metastasis and tumors are extremely heterogeneous, and therefore each stage should be treated as a different condition. It has also been recently demonstrated that plasma ctDNA is suitable for monitoring treatment response and also for the early detection of acquired resistance mechanisms (e.g., T790M in NSCLC) (74). These and other studies are laying the foundations for the development of cfDNA as a new and non-invasive source of material that can be used routinely when testing for predictive biomarker for targeted therapies.

The value of CTCs analysis in lung cancer is currently mainly related to prognosis, but there is an increasing interest in the development of new techniques for molecular characterization of CTCs. It is not fully understood whether CTCs are the only cause of metastasis, but it has been reported that their counts correlate with a poorer prognosis in lung cancer and in other tumor types, although there is still a need for clinical validation of these findings, particularly in lung cancer.

The information obtained from liquid biopsies, together with imaging analysis, replacing invasive tissue biopsies, will probably guide treatment decision and hopefully will improve the outcome for lung cancer patients, having also the potential for early diagnosis of tumors that are not yet visible on imaging.

Acknowledgements

Funding: This study was supported by Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, and Fondo Europeo de Desarrollo Regional (PI13/01806, PIE14/00064), Joan Rodés fellowship (JR14/00017 to AR).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

16. Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aus Med J 1869;14:146-9.


Comprehensive Cancer Network 21st Annual Conference (Hollywood, FL; March 2016).


